Higher max dose guidance for semaglutide offers hope
When the scale won't budge, STEP UP! Higher-dose weight loss injections now available.
A new study increases max-dose guidance for semaglutide. This offers hope for those who didn't reach their weight goals. The Injection and Infusion Clinic of ABQ now provides higher-dose weight loss injections, backed by the STEP UP trial, which showed 20.7% average weight loss with higher-dose semaglutide. 33.2% of participants lost over 25% of their body weight. Ideal for those who plateaued, this science-backed treatment supports long-term weight management with personalized care.
Albuquerque, NM - Feb 10, 2025 - The Injection and Infusion Clinic of ABQ is excited to announce the availability of new higher-dose weight loss injections as supported by the recent findings of the STEP UP clinical trial. These advanced treatment options are now available to patients in Albuquerque and beyond, offering renewed hope for those who didn't achieve results previously on the standard doses.
The STEP UP trial, a pivotal 72-week study, demonstrated remarkable outcomes for patients using the higher-dose semaglutide. Participants experienced an average of 20.7% total body weight loss, significantly exceeding the results seen with the standard 2.4 mg dose. This new dosing option is a game-changer for individuals seeking long-term, effective solutions to manage their weight and improve overall health.
'The STEP UP trial results are a major breakthrough in the field of weight loss,' said KC Raver, Clinic Director at The Injection and Infusion Clinic of ABQ. 'We're thrilled to bring this innovative treatment to our patients, especially those who've felt stuck in their weight loss journey or haven't seen success with other methods. These higher doses of semaglutide offer a proven, evidence-based solution to help people achieve their health goals.'
Why Choose Higher-Dose Semaglutide?
Patients who previously didn't see results or experienced plateaus can now benefit from this enhanced treatment option. Key benefits of the higher-dose semaglutide include:
Greater Weight Loss: Patients in the STEP UP trial achieved an average weight reduction of 20.7% — a significant improvement over standard-dose therapies.
Increased Success: 33.2% of participants on the higher dose lost 25% or more of their body weight, compared to 16.7% with the 2.4 mg dose.
Science-Backed Results: Clinical evidence highlights the safety and effectiveness of this higher dose, offering new hope for patients who felt like they'd exhausted other options.
Semaglutide is a GLP-1 receptor agonist, a class of medications originally developed for diabetes management that has also been shown to support weight loss. These medications work by regulating appetite and glucose metabolism. The findings of the STEP UP study suggest that higher doses may be beneficial for individuals who have plateaued in their weight loss journey or did not achieve desired results with lower doses.
'The results of this study provide additional data on how higher doses of semaglutide may impact weight loss outcomes,' said KC Raver, Clinic Director at The Injection and Infusion Clinic of ABQ. 'Offering this option allows us to tailor treatments based on emerging clinical evidence and patient needs.'
The Injection and Infusion Clinic of ABQ integrates evidence-based weight management strategies with individualized patient care. Those interested in learning more about the higher-dose semaglutide treatment can schedule a consultation to discuss their options.
For more information, visit or call 505.445.4300.
About The Injection and Infusion Clinic of ABQ
The Injection and Infusion Clinic of ABQ specializes in weight management and wellness solutions, offering treatments backed by clinical research. With a commitment to personalized care, the clinic empowers patients to achieve lasting health outcomes.
Contact:
The Injection and Infusion Clinic of ABQ
Phone: 505.506.7775
Email: [email protected]
Website: www.infusionclinicabq.com
Media Contact
Company Name: Well Life ABQ
Contact Person: KC Raver
Email: Send Email
Phone: 505-506-7775
Address:8400 Osuna Rd, NE Suite 5C
City: Albuquerque
State: NM
Country: United States
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
12 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
16 hours ago
- Yahoo
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo1 Safety and tolerability of the higher dose of Wegovy® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg)1 The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks*1: semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4%5% or more weight loss 93.2% 92.5% 35.7%When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks*1: semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9%25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trialsNovo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy®Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 abmo@ Liz Skrbkova (US) +1 609 917 0632 lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Ida Schaap Melvold +45 3077 5649 idmg@ Sina Meyer +45 3079 6656 azey@ Max Ung +45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568 fptr@ References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment PR250621-ADA-STEP-UP
Yahoo
29-05-2025
- Yahoo
New Mexico report reveals far higher homelessness numbers than federal count
May 29—Before calling the sidewalks of Albuquerque home, Trina Hunter was a manager at Wendy's while volunteering at St. Martin's Hospitality Center on the side and raising a teenager. Four years after escaping domestic abuse, Hunter said she has felt the effects of homelessness in various ways — mental illness, slipping hygiene and constant relocating. But the 40-year-old said she wakes up every day with hopes of something better on the horizon. "I survived, and I'll keep surviving," she said, sitting on the sidewalk surrounded by everything she owns — all stuffed into two suitcases. "We've got to swallow it, choke it down, and keep going. Some of us do so much to make our way back home, but for some of us, it's too late." It's no secret that thousands of New Mexicans experience homelessness every year. But a recently released state Department of Health report found that number could be at least as high as 30,000 people homeless from 2019 to 2023, a number 2-to-4 times higher than other counts. The NMDOH study relied on hospital visitation records with indicators of homelessness instead of traditional point-in-time methods. "We're able to capture a lot more in this system," said NMDOH epidemiologist and one of the study's researchers, Hayley Peterson. "And so I definitely think it's a good, reliable way that we've done it here, but I definitely don't want to discount the good work that (the New Mexico) Coalition to End Homelessness has done." Research by Peterson and NMDOH epidemiologist Dylan Pell reviewed data from the New Mexico Syndromic Surveillance Program (NM-SSP), which collects visitation records from most nonfederal hospitals across the state from 2019 to 2023. They found that 30,882 unique patients, an average of about 9,100 per year, had at least one hospital record indicating homelessness across the state. Their method relied on records from medical facilities with diagnosis codes for homelessness, inadequate housing, or housing instability — or if the patient's listed address contained the word "homeless" or some other indicator. They also looked through patient records, for terms such as "homeless," "unhoused," "unsheltered" and "transient." Bernalillo County had the highest number of people experiencing homelessness, according to the NMDOH research. The report stated that 18,611, or about 60% of the total, were in the state's most populous county. That was followed by Santa Fe County, at 2,052 (7%), Doña Ana County, at 1,792 (6%), and San Juan County, at 1,479 (5%). Many governments, including the city of Albuquerque, rely on the yearly point-in-time, or PIT, count to assess the number of people experiencing homelessness. The count occurs yearly on Jan. 29 and has dozens of volunteers counting the number of people staying on the streets and those in shelters. For Peterson and Pell, the goal of their research was to supplement the work of PIT Count volunteers, not replace it. "I would say it's also a reliable measure of homelessness as it exists in health care systems in New Mexico, primarily emergency rooms," Pell said. "But we're not counting people who don't go to the emergency room. We're not counting people who aren't patients in these health systems." That work falls on the New Mexico Coalition to End Homelessness, which states in its yearly reports that the PIT count likely undercounts the population of unhoused New Mexicans. "There are limitations to the PIT Count — inherent to the definitions and regulations that the U.S. Housing and Urban Development requires counts to adhere to — that inevitably result in an undercount of the true size of the population of people experiencing homelessness," the New Mexico Coalition to End Homelessness 2024 report stated. Mark Oldknow, the associate director of the New Mexico Coalition to End Homelessness, said it takes a small army to complete the yearly count. But that data serves a different purpose. "We all know that even using different methodologies and different sampling structures, we're never getting to anything other than a number that suggests that this is the floor, not the ceiling," Oldknow said. But there's no feeling of competition between the two methods, Oldknow said, since the mission to understand the true scope of the problem is shared. "I'd like people to understand that this is a daunting problem. It's a social problem that affects us all, whether or not we pay attention," Oldknow said. For Peterson, some of the more striking findings included higher-than-expected populations of people experiencing homelessness under 5 years old and over 65. Their research also concluded that people experiencing homelessness require more frequent medical care. On average, the report found that unhoused residents visited the hospital 5.9 times over the five-year study period. "A person with poor health might be unable to work or more likely to lose their job leading to financial instability and unstable housing, and a person without stable, clean, and safe housing will be more likely to experience negative health outcomes," the report read. The report also noted disparities in gender and racial data. Over two-thirds of the patients were male, about 39% were Hispanic, another 39% were white, 5% were American Indian or Alaska Native, 6% were Black, and less than 1% were Asian or Pacific Islander. None of what the study examined came as a surprise to Rachel Biggs, the chief strategy officer of Albuquerque Health Care for the Homeless. For Biggs, whose work includes advocacy and oversight of the health care system mandated to serve those without housing, the report can have a significant impact. "We can point to some data points that show real numbers here in New Mexico, from hospital data to show the extent of the problem, to show the disparities across race and ethnicity, to show that the solutions need to be focused on housing," Biggs said.
